Login to Your Account

Other News To Note

Wednesday, June 5, 2013
• Sinovac Biotech Ltd., of Beijing, said its new drug application for its EV71 vaccine was filed and accepted by the Beijing Drug Administration. Sinovac completed Phase III studies in March showing a 95 percent efficacy rate for the vaccine against hand, foot and mouth disease caused by enterovirus 71.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription